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analysis
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X-ray absorption ﬁne structure analysisBisphosphonates (BPs) have been widely, efﬁciently, and safely used for the treatment of various bone-related
diseases such as osteoporosis. However, concerns about jaw osteonecrosis associated with oral treatment
(medication-related osteonecrosis of the jaw [MRONJ]) have been increasing. Although many risk factors for
MRONJ have been elucidated, its precise etiology and methods of prevention remain unknown. In this study,
we have applied various elemental analysis methods for MRONJ specimens (e.g., X-ray ﬂuorescence with
synchrotron radiation [SR-XRF], particle-induced X-ray emission [PIXE], X-ray absorption ﬁne structure
[XAFS]) in order to reveal the accumulation and chemical state of trace bone minerals. In four MRONJ sequestra,
the characteristic localization of copper (Cu)was observed by SR-XRF. Usingmicro-PIXE analysis, Cu looked to be
localized near the edge of the trabecular bone. The chemical state of the accumulated Cu was estimated using
XAFS and the possibility of a Cu–BP complex formation was assumed. Thus, in this study we argue for the
feasibility of the trace element analysis to evaluate the potential pathophysiological mechanism of MRONJ.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
As synthetic analogues of pyrophosphate compounds, bisphosphonates
(BPs) are selectively uptaken by osteoclasts and strongly inhibit bone
resorption by inducing apoptosis (Iwata et al., 2006; Rodan and
Fleisch, 1996; Viereck et al., 2002). BPs can be classiﬁed into two
groups: non-nitrogen containing and nitrogen-containing. Nitrogen-
containing BPs, a new-generation of BPs with different action
mechanisms than non-nitrogen containing BPs, have been widely
used for the treatment of osteoporosis, malignant hypercalcemia, solid
cancers inducing bone metastasis, Paget's disease, and multiple myelo-
ma (Russell et al., 2007; Yoneda et al., 2010). However, sinceMarx et al.
in 2003 reported the ﬁrst case of jaw osteonecrosis in a cancer patient
received BPs following dental treatment (Marx, 2003), the reports of
medication-related osteonecrosis of the jaw (MRONJ) have been
increasing (Bamias et al., 2005). Although many factors related to
MRONJ have been identiﬁed (Yoneda et al., 2010), such as BP formula-
tion (Marx et al., 2007), local factors (e.g., tooth extraction and dentalepartment, Graduate School of
niversity, Japan.
. This is an open access article underimplants) (Ruggiero et al., 2004; Marx et al., 2005), systemic factors
(e.g., anticancer drugs or steroids) (Khamaisi et al., 2007), genetic
factors (e.g., presence of P450 CYP2C8) (Sarasquete et al., 2008), and
other factors (e.g., drug use, smoking, alcohol) (Matthew and David,
2008;Wessel et al., 2008;Migliorati et al., 2006), the precise risk factors
for developing MRONJ are unknown. Although guidelines and position
papers suggest systemic management, patient education, antibacterial
mouth rinse, oral hygienemaintenance, and BPwithdrawal for patients
classiﬁed as high-risk, there are no clear evidence-based medicine for
MRONJ treatment (Yoneda et al., 2010; Ruggiero et al., 2009). Therefore,
the establishment of diagnostic markers forMRONJ risk assessment and
prevention is urgently needed.
Experimental studies to reveal changes in the chemical components
of bone exhibitingMRONJ development have been carried out for serum
biomarkers and bone minerals. The relationship between serum bio-
markers (e.g., parathyroid hormone (Kim et al., 2013) or C-terminal
telopeptide of collagen I (Marx et al., 2007)) and MRONJ development
has been studied, although a clear linkage has not been found.
Concerning bone minerals, Lowe et al. reported that plasma zinc (Zn)
concentration in osteoporosis patients was signiﬁcantly lower than
that in healthy persons, while no signiﬁcant changes were observed in
plasma copper (Cu) concentration (Lowe et al., 2002). Koçer et al.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of rats (Koçer et al., 2013). Therefore, Zn and Cu analysis may be the
possible indices to reveal the MRONJ pathophysiological mechanism.
However, no literature presents a compelling argument for how to eval-
uate Zn and Cu levels in MRONJ patients. In addition, those studies
discussed the average concentration of Zn and Cu in serum, plasma,
and entire tissue. However, those elements would not be homoge-
neously distributed in bone. Concerning Zn, Gomez et al. demonstrated
that it can be detected at the osteon surface and the calciﬁcation front
(Gomez et al., 1999). Therefore, the quantitative and distribution analy-
ses of Zn and Cu in sequestrum of MRONJ patients might provide useful
information to reveal pathophysiology or further risk assessment.
However, the concentration of these elements in bone is quite low, so
a highly sensitive and position-speciﬁc elemental analysis method is re-
quired for this purpose. The authors have applied the detection and
chemical state analysis methods of metallic trace elements to analyze
soft tissues (Sugiyama et al., 2014, 2015; Uo et al., 2015). Synchrotron
radiation-induced X-ray ﬂuorescence spectroscopy (SR-XRF) provides
information on elements in specimens and X-ray absorption ﬁne
structure (XAFS) analysis provides information on the chemical state
of target elements. Using these methods, trace metallic elements in
biopsy specimens can be detected and analyzed.
In this study, hence, we focus on the distribution and chemical state
of trace essential elements contained in bone. SR-XRF and micro-
focused particle-induced X-ray emission spectroscopy (micro-PIXE)
were applied to an elemental distribution analysis of thin-sectioned
specimens of MRONJ sequestrum. The chemical state for concentrated
elements in bone was also estimated with an XAFS analysis of the
concentrated regions. Subsequently, we estimated the localization of
trace mineral accumulation and distribution, and their chemical state
in the MRONJ sequestrum.
2. Materials and methods
2.1. Bone specimens
Bone specimens were supplied by Jichi Medical University Hospital,
Tochigi, Japan. The samples included four MRONJ-induced sequestrum
specimens that were exposed to BP therapy (alendronate [ALN] and
zoledronate [ZOL]) and two torus mandibularis specimens that were
not exposed to BP therapy. Torusmandibularis is non-neoplastic hyper-
plasia disease. Histopathologically, laminar bone cortex structure with-
out dysplasia is observed. Therefore, we used torus mandibularis as the
control (CON). All patients provided informed consent and the study
protocol was approved by the Ethical Committee of Jichi Medical
University Hospital (A14-181). Table 1 shows the clinical data for all
specimens.
Specimen #1 included mandibular bone tissue from a patient who
had received alendronate for osteoporosis. She had been treated with
a bridge-type prosthesis eight years earlier, and received BP therapy be-
ginning ﬁve years earlier. Direct contact between the two dummy teeth
and gingiva and bone exposure in the same region were observed. ThisTable 1
Clinical data for the patients.





#1 F 72 MRONJ ALN p.o. 2 5 years Osteoporosi
#2 F 51 MRONJ ALN p.o. 2 6 years Osteoporosi
#3 F 65 MRONJ ZOL i.v. 2 2 years Bone metas
mammary c
#4 M 74 MRONJ ZOL i.v. 2 2 years Bone metas
prostatic ca
#5 M 64 Torus mandibularis – – – –
#6 F 48 Torus mandibularis – – – –
MRONJ—medication-related osteonecrosis of the jaw; F—female; M—male; ALN—alendronate;patient was diagnosed with MRONJ in light of clinical ﬁndings, histo-
pathological ﬁndings, and her medical background of receiving BPs.
Specimen #3 included mandibular bone tissue from a patient who
had received ZOL for bone metastasis of mammary carcinoma. After
her right mandibular molar was extracted, she received BP therapy for
a period of two years. Since that time, she experienced strong pain,
pus discharge, and bone exposure. This patient was diagnosed with
MRONJ using clinical ﬁndings, histopathological ﬁndings, and medical
background.
Specimen #5 included mandibular bone tissue from a patient who
had no systemic complications and had not received BPs. He presented
to our ofﬁce with a complaint after bone resection, wherein there was
bone prominence in the mandibular lingual region. The denture had
pressured onto this area, and the pain and a decubital ulcer were ob-
served. The patient was diagnosed with torus mandibularis using clini-
cal and histopathological ﬁndings. The clinical history of the remaining
specimens (#2, #4, and #6) is described in “Supplementary material.”
All bone specimens were ﬁxed in 4% phosphate-buffered saline–
formalin. Decalciﬁcation was performed in ethylenediaminetetraacetic
acid (EDTA) for three to ﬁve days. The specimens were embedded in
parafﬁn and sliced into two thicknesses (4 μm and 8 μm). The 4-μm
sample, which was stained with hematoxylin and eosin (H&E), was
placed adjacent to the 8-μm sample on Kapton ﬁlm (12.5 μm thick; Du
Pont-Toray Co., Ltd., Tokyo, Japan) and subjected to the following
elemental analyses.
2.2. Elemental distribution analysis
2.2.1. Synchrotron radiation X-ray ﬂuorescence spectroscopy (SR-XRF)
analysis
XRF analyses of the six specimens were carried out at BL-4A of the
Photon Factory at the High Energy Accelerator Research Organization
in Tsukuba, Japan. The incident X-ray (12.9 keV) was focused to a 30-
μm region using polycapillary optics, and the specimen was irradiated.
The specimen stage was scanned in the X–Y plane, two dimensionally,
to obtain elemental distribution images. The scanning areas varied
within several millimeters, and the scanning steps varied from 40 μm
to 100 μm. The obtained XRF data were processedwith PyMCA software
(Version 4.7.3) after elemental distribution images were obtained.
2.2.2. Preparation of the thin ﬁlm standard for quantitative analysis
Thin ﬁlm standard specimens of zinc (Zn) and copper (Cu) were
prepared using organometallic compounds and methacrylate resins.
First, we prepared the resin monomer matrix: bisphenol A-glycidyl
methacrylate (Shin-Nakamura Chemical, Wakayama, Japan) and
triethylene glycol dimethacrylate (Tokyo Chemical Industry, Tokyo,
Japan) were mixed to a 1:2 weight ratio to be a base monomer. Benzoyl
peroxide (Tokyo Chemical Industry, Tokyo, Japan) and camphorquinone
(Sigma Aldrich, St. Louis, MO, USA)were added as a polymerization initi-
ator. The acetylacetonates with Zn and Cu (Dojindo, Kumamoto, Japan)
were dissolved into themonomer at 0 to 40ppm. Thepreparedmonomer
was spread over the glass plate and polymerized with photo-curing andease Corticosteroid Site Trigger dental treatment and oral condition
s – Mandibula Pressure onto the gingiva from two
dummy teeth of bridge-type prostheses
s PSL 5 mg Mandibula Tooth extraction
tasis of
arcinoma
– Mandibula Tooth extraction
tasis of
rcinoma
– Maxilla Chronic apical periodontitis
– Mandibula –
– Mandibula –
ZOL—zoledronate; PSL—prednisolone; p.o.— per os; i.v.—intravenous.
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sured inmicrometers. The XRF analyses of the standardswere carried out
with the same conditions as described above. The co-relation between
the ﬂuorescence X-ray intensity and the element concentration were
obtained from the calibration curves.
2.2.3. Micro-focused particle induced X-ray emission spectroscopy (Micro-
PIXE) analysis
In order to visualize the high-resolution elemental distribution
images, micro-PIXE analysis was carried out at the National Institute
of Radiological Sciences (Chiba, Japan). An accelerated and micro-
focused proton beam (3.0MeV, 2-μmbeam diameter) with raster scan-
ning was applied over the target area of the specimen (500 × 500 μm).
The generated characteristic X-rayswere collected using Si(Li) andCdTe
detectors to obtain the elemental distribution images and the
characteristic X-ray spectra. The obtained data were processed with
OMDAQ2007 software (Version 1.3.71.669), and the elemental distribu-
tion images and characteristic X-ray spectra of the region of interest
were collected.
2.3. X-ray absorption ﬁne structure (XAFS) analysis
The X-ray absorption spectrum around the speciﬁc energy of the tar-
get elements called the “absorption edge” reﬂects the surrounding
structure and the chemical state of the element. The speciﬁc structure
on the spectrum is known as XAFS. Comparison of the XAFS spectrum
with those of reference materials can reveal the chemical state of the
target elements. For the typically accumulated metallic elements,
XAFS analyses were carried out to determine the chemical states of
the elements. XAFS analyseswere also conducted at BL-4Aof the Photon
Factory. XAFS spectra of accumulated Cu in sequestrum specimenswere
measured with the ﬂuorescent XAFS method. For comparison, Cumetal
and copper (I) oxide (Cu2O) were also measured as reference
specimens.
2.4. Computational procedure of XAFS spectra
Cu-incorporated hydroxyapatite (Cu–HAp) and Cu-alendronate
complex (Cu–ALN) were not available as reference materials for XAFS
measurements. Therefore, theoretical Cu K-edge XAFS spectra for
those materials were simulated using the ﬁrst principles plane wave
basis pseudopotential method (CASTEP code) (Clark et al., 2005; Gao
et al., 2008). Generalized gradient approximation (GGA) was used as
an exchange–correlation interaction, and the plane wave cutoff energy
was set to 400 eV. Spin-polarization was considered in the calculations,
and on-site Coulomb interaction (U=6.5 eV)was used for Cu-d orbital.
To account for a core hole effect, a special ultrasoft pseudo-potential de-
signed for excited atoms with a core hole was employed in the excited
Cu atom. Theoretical transition energy was estimated by the same
method as described in a previous report (Mizoguchi et al., 2009). This
method can quantitatively reproduce the amount of chemical shift
(Mizoguchi et al., 2009). The detailed conditions for calculations follow-
ed the procedures outlined in a previous report (Matsunaga et al.,
2010). The crystal structure of Cu–HAp and Cu–ALN was optimized
until the residual force lowered to 0.03 eV/Å, as described in previous
reports (Matsunaga et al., 2010; Demoro et al., 2012).
3. Results
3.1. Histopathological analysis
Fig. 1 shows the H&E stained images of the specimens #1 (ALN), #3
(ZOL), and #5 (CON). All specimens had characteristic features of
necrotic bone: osteomyelitis containing necrotic bone with no
osteoblasts, no osteoclasts, and granulation tissue with inﬂammatory
cell inﬁltration. Moreover, in specimens #1 and #3, ﬁbrosis of themedullary space and Actinomyces colonies were observed. (The H&E
stained images of specimens #2 [ALN], #4 [ZOL], and #6 [CON] are
shown in Fig. S1 of the “Supplementary material.”).
3.2. Elemental distribution analysis
Fig. 2 shows the elemental distribution (phosphorus [P], calcium
[Ca], Cu, and Zn) images of entire specimens #1 (ALN), #3 (ZOL), and
#5 (CON) obtained using SR-XRF with 100 μm step. The observation
regions in each were the same as the regions shown in Fig. 1A. The P
distribution images show the entire shape of the specimens and the
similarity of the observational regions could be conﬁrmed by the
shape similarity with the H&E stained images shown in Fig. 1. Ca
distribution images of all ﬁgures show no characteristic localization
and complete demineralization could be observed. In contrast, the Cu
distribution images show signiﬁcant differences between MRONJ se-
questrum (#1 and #3) and control (#5). Characteristic accumulation
(line-shaped, not diffusible) of Cu was observed in the MRONJ seques-
trum, hence no accumulation was observed in the control. Zn showed
a similar tendency. In order to visualize more detailed distribution of
Cu and Zn in specimens #1 and #3, the white box regions of Fig. 2
were analyzed using SR-XRF with a higher resolution (40 μm step), as
shown in Fig. 3. MRONJ sequestrum showed characteristic distribution
of Cu and Zn; these elements were clearly localized around the bone
trabecula structure.
The ﬂuorescence X-ray (XRF) spectra of Cu-localized spots shown in
Fig. 2 are compiled in Fig. 4 in order to compare the intensity of the
ﬂuorescence X-ray of the detected elements. In order to compare the ac-
cumulated elements between the regions with characteristic elemental
accumulation, XRF spectra at the spots (indicated with white arrows in
Fig. 2) are shown in Fig. 4. Signiﬁcantly strong peaks of Cu were
observed inMRONJ specimens (#1 and #3). Very small peaks of Ca indi-
cated successful demineralization of all specimens. (The corresponding
data for Figs. 2 to 4 of specimens #2, #4, and #6 are shown in Figs. S2 to
S4 of the “Supplementary material”.)
Fig. 5 shows high-resolution Cu distribution images of specimens #1
and #3 obtained bymicro-PIXE of thewhite rectangular region in Fig. 3.
The H&E stained images of the corresponding region are also shown.
Sulfur (S) was contained in the organic components of the sequestrum,
thus the entire shape of the observation region could be identiﬁed and
coincided well with the H&E image. Cu showed obvious localization
along the edge of the bone trabecula.
Fig. 6 shows the calibration curve for the Cu standard specimens.
Good linearity was obtained for the relationship between the element
concentration and the ﬂuorescence X-ray intensity, which were nor-
malized with the specimen thickness for both elements. The raw inten-
sity and thickness (8 μm)normalized intensity of theﬂuorescence X-ray
of Cu at spots (#1, #3, and #5 in Fig. 2, and #2, #4, and #6 in Fig. S2 in
the “Supplementary material”) are shown in Table 2. Using this relation
for the above intensities of Cu at the localized spots could also be esti-
mated, as shown in Table 2. The extremely high concentration of Cu at
the accumulated spots in specimens #1 to #4, which were derived
from the MRONJ specimens, could be identiﬁed compared to the bone
that were not exposed to BPs (specimens #5 and #6). Therefore, an
abnormally high level of Cu accumulation in MRONJ sequestra was
revealed.
3.3. XAFS analysis and the simulation
Fig. 7 shows the XAFS spectra of Cu at spots #1 and #3 of specimens
#1 and #3, and also that of the referencematerials (Cumetal and Cu2O).
The XAFS spectra suggested that Cu in spot #1 and spot #3 was in a
similar chemical state, but this state differed from that of the reference
materials (e.g., Cu metal and oxide). Therefore, the accumulated Cu in
MRONJ sequestra was not in those states. The calculated XAFS spectra
of Cu metal, Cu–ALN, and Cu–HAp is also shown in Fig. 7. It was
Fig. 1.Histopathological images (hematoxylin and eosin (H&E) staining) of specimen #1 exposed to alendronate (ALN), specimen #3 exposed to zoledronate (ZOL), and the control spec-
imen #5 not exposed to BPs (CON). (A) lowmagniﬁcation and (B) highmagniﬁcation. All sequestrum specimens had the characteristics of necrotic bone: no osteoblasts in the bone cavity
(⁎), no osteoclasts at the edge of bone trabecula, and granulation tissuewith inﬂammatory cells.Moreover, in specimens #1 and#3, ﬁbrosis ofmedullary space and Actinomyces colony (⁎⁎)
were observed.
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simulation because the measurements were affected by various factors
(e.g., fractuations and defects of the structure of target substance and
also fractuations of measurement facilities). Therefore, measured and
simulated spectra were not completely matched, even for Cu metal
that had a simple crystal structure. Therefore, the validity of simulation
can be estimated by the absorption edge energy and the outline of the
spectrum around the edge. To show the outline of the calculated
spectra, smoothened spectra are shown in Fig. 7. (The original spectra
are shown in Fig. S5 of the “Supplementary material”.) The outline of
the measured Cu metal spectrum around the absorption edge
(8975–8990 eV),which showed a gradual increase, waswell reproduced
in the simulation, thus those simulated spectrawere valid. In comparison
with the spectra of spots #1 and #3 to the simulated spectra of Cu–ALN
and Cu–HAp, the absorption edge energy of spots #1 and #3 (Emeasured)was closer to that of the simulated Cu–ALN (ECu–ALN) than that of the
Cu–HAp (ECu–HAp). In addition, a gradual increase of the measured
absorption spectra in spots #1 and #3 around the absorption edge
(8980–8990 eV) was similar to that of Cu–ALN.
4. Discussion
Bisphosphonates have a high afﬁnity for bone minerals (Rogers
et al., 1997; Russell et al., 2007). They comprise two phosphonate
groups attached to a single carbon atom, the molecular framework of
a P–C–P structure, which can chelate calcium ions through the
phosphonate groups. BPs are incorporated into osteoclasts during
bone remodeling, and bone resorption is inhibited by inducing
apoptosis of osteoclasts (Rogers et al., 2000; Russell et al., 2007).
Therefore, BPs are a very effective treatment for various bone diseases.
Fig. 2. Elemental distribution images of specimens #1, #3, and #5 obtained by SR-XRF. The observation areas were the same as those for Fig. 1(A) in each specimen. Clear Cu and Zn ac-
cumulationmaybe observed over the entire area of theMRONJ sequestra (#1 and#3). In contrast, accumulation could not be identiﬁed in the control specimen (#5). P and Ca could not be
clearly detected in all specimens.
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effective mechanism to identify the biomarkers or indices of MRONJ.
Nitrogen analysis has also been used to estimate BP accumulation in
bone (Schaudinn et al., 2012), but an effective single factor has not
been identiﬁed.Fig. 3. The detailed elemental distribution images of thewhite rectangular region of Fig. 2 for spe
in the MRONJ sequestra. Moreover, the accumulation of these elements was similarly line-shaIn this study, we revealed a peculiar change of bone minerals,
especially Cu, in the MRONJ sequestrum. Specimens #5 and #6, which
were not exposed to BP therapy, showed no characteristic accumulation
of Cu (Figs. 2 and S2). In contrast, specimens #1 to #4 (MRONJ
sequestra) showed clear and line-shaped accumulation of Cu (Figs. 2,cimens#1 and#3 obtained by SR-XRF. Signiﬁcant Cu and Zn accumulationwere observed
ped.
Fig. 4. XRF spectrum at the accumulated spots (#1 to #3) of Cu is indicatedwith arrows in
Fig. 2. Spot #1 (ALN) and spot #3 (ZOL) showed clear ﬂuorescence X-ray peaks for Cu,
whereas those of Ca and Fe were weak. Spot #5 (CON) showed a weak elemental peak.
Fig. 6. Calibration curves of the prepared thin ﬁlm standard specimens for Cu. A good lin-
ear relationship between the elemental concentration and thickness-normalized ﬂuores-
cence X-ray intensity was obtained.
45T. Sugiyama et al. / Bone Reports 3 (2015) 40–473, S2, and S3). Detailed distribution in Fig. 5 shows Cu localization along
the edge of the bone trabecula. At Cu localization spots, XRF spectra
(Figs. 6 and S4) show extremely strong peaks assigned to Cu compared
to that of Ca. The low intensity of Ca peaks suggests the complete demin-
eralization treatment of all bone specimens. Hence, Cu was clearly
retained and localized. As shown in Table 2, the concentrations of Cu in
the MRONJ sequestra specimens (#1 to #4) were estimated to be be-
tween 600 to 5000 ppm. In contrast, Cu concentrations in the control
specimens (#5 and #6) were estimated at around 20 to 100 ppm. The
concentrations of Cu in the MRONJ specimens were more than two or-
ders higher than that in the normal bone. The Cu concentration of normal
bone tissue has been reported as 0.77 ± 0.28 (ppm) for Cu (Basle et al.,
1990). The estimated Cu concentrations in MRONJ sequestra were more
than three orders higher than the reported average Cu concentration in
normal bone. In those specimens, demineralization could be completed
because Ca and Pwere slightly detected for entire specimens in elemental
distribution images (Figs. 2, 3, S2, and S3) and also in XRF spectra (Figs. 4Fig. 5.High-resolution elemental distribution images for specimens#1 and#3 obtained bymicr
identiﬁed by S distribution. Cu looked to be localized among the near edge of the bone trabecuand S4). In normal bone, Cu is incorporated in the HAp-substituting Ca
site. This is one possible candidate where Cu may accumulate. However,
if Cu is incorporated in HAp of MRONJ sequestrum, it could be
demineralized with EDTA solution. Therefore, we suggest that Cu may
form and retain a stable complex that cannot be removed by the demin-
eralization process.
Considering the form of accumulated Cu, it is important to note that
Cu accumulated near the edge of bone trabecular (Fig. 5). In the vicinity
of bone trabecula, osteoclasts exist in a high population for bone
resorption and bone is vigorously remodeled. It is well known that
BPs incorporated into osteoclasts inhibit bone resorption. Therefore,
BP concentrations in Cu-accumulated regionswould be high (for the os-
teoclast population) and there would be a generally high concentration
of BPs. Therefore, Cu–BP complex could be suggested as a possible
candidate substance for the accumulated form of Cu.o-PIXE andH&E stain of the corresponding region. The shape of the entire specimen can be
la.
Table 2
Fluorescence X-ray intensities of Cu at spot #1 to spot #6 and the estimated concentration




with thickness (8 μm)
Estimated
concentration (ppm)
#1 ALN 5474 684 2900
#2 1102 138 590
#3 ZOL 9372 1170 5000
#4 5915 739 3200
#5 CON 47 6 22
#6 190 24 99
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because of their electrical and optical properties (Katz et al., 1991;
Snover et al., 1996; Neff et al., 1999) as well as the pharmacological
effects (Demoro et al., 2012; Wolf and Stoller, 1994). The puriﬁed sub-
stances of Cu–incorporated HAp (Cu–HAp) and Cu–BP complex were
not available for testing. Therefore, we simulated the XAFS spectra of
the two substances [Cu–HAp and Cu–alendronate complex (Cu–ALN)]
and compared the measured XAFS spectra from specimen #1 and
specimen #3 (Fig. 7). Because of the limitation of theoretical simulation,
the complete consistency of the measured spectra of specimen #1 and
specimen #3 and the simulated spectra depicted in Fig. 7 could not be
achieved. Features of the XAFS spectra at spots #1 and #3 include a
higher absorption edge energy (Emeasured) and a gradual increase of
the absorption around the edge (8980–8990 eV). Measured spectra of
Cu metal and Cu2O, and simulated spectra of Cu–HAp could not repro-
duce the aforementioned features. The simulated spectrum of Cu–ALN
can only reproduce the aforementioned features among the measured
and simulated materials. In consideration of the accumulated location
of Cu (near the edge of bone trabecula) and the similarity in XAFSFig. 7. The measured spectra (meas) of the MRONJ sequestra and the reference materials
(Cu metal and Cu2O) and simulated spectra (sim) of the Cu-alendronate complex (Cu–
ALN), Cu–incorporated HAp (Cu–HAp), and Cu metal. The measured spectra of the
MRONJ sequestrawere different fromCumetal and Cu2O. Absorption edge energy ofmea-
sured spectra, simulated spectra of Cu–ALN and Cu–HAp are indicated as Emeasured, ECu–ALN,
and ECu–HAp, respectively. The absorption edge energy and the shape of spectra of themea-
sured spectra at spots #1 and #3 were similar to those of the simulated spectrum of Cu–
ALN when compared with other materials.spectra, it may be assumed that Cu accumulated and localized in the
MRONJ sequestrum as Cu–BP complex, e.g., Cu–ALN.
In this study, we analyzed only four MRONJ sequestra and two
control bone specimens without BP administration. Because of the
small specimen size, it is difﬁcult to conclusively state the effects of Cu
accumulation and its relationship with MRONJ pathogenesis. However,
the characteristic accumulation of Cu in MRONJ sequestra in a high
concentration, even after demineralization, could not be explained as
incorporation into HAp. In addition, with the localization of Cu along
the edge of the bone trabecula and the similarity of XAFS spectra of Cu
in the MRONJ sequestra and Cu–ALN, the possibility of a relationship
between Cu and BP accumulation could be suggested.
The present study was a preliminary trial to estimate the feasibility
of trace metallic element analysis for the study of MRONJ pathogenesis.
Therefore, a future study is necessary to conﬁrm the aforementioned
assumption concerning the Cu and BP relationship and its effect on
MRONJ:
1) Cu accumulation and distribution should be estimated for MRONJ
sequestra and for other bone diseases with and without BPs.
2) BP distribution in MRONJ and control bone specimens and the
relation to Cu distribution should be estimated; and the chemical
state of Cu accumulated in MRONJ using the XAFS measurement
compared with other various Cu compounds and synthesized
Cu–HAp, Cu–ALN and other Cu–BPs complexes should be conﬁrmed.
Future studies concerning trace metallic element accumulation and
localization in MRONJ sequestrum and their relation to Cu content in
blood, urine, and other tissues might be useful indices to reveal the
pathophysiological mechanism of MRONJ. In clinical application, a posi-
tion paper from the American Association of Oral andMaxillofacial Sur-
gery (Ruggiero et al., 2009) suggests “development of valid MRONJ risk
assessment tools” for future study. The abnormal accumulation of Cu in
bone might be a possible candidate index for MRONJ risk assessment.5. Conclusion
In this study, we successfully detected the characteristic accumula-
tion of Cu in MRONJ samples by using SR-XRF and micro-PIXE, and the
chemical state of Cu was estimated using XAFS. The estimated concen-
tration of accumulated Cu in the MRONJ sequestrum was much higher
than that in normal bone, even after demineralization. From the distri-
bution and chemical state of the accumulated Cu, the possibility of accu-
mulation as a Cu–BP complex was assumed. Hence, the trace elemental
analysis may provide useful indices to reveal the pathophysiological
mechanism of MRONJ.Acknowledgments
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